Trial reportFrontiers in endocrinology2023
Risk factors and predictive model for recurrence in papillary thyroid carcinoma: a single-center retrospective cohort study based on 955 cases.
Trial report in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prediction models for postoperative recurrence in papillary thyroid carcinoma: a systematic review and critical appraisal.Frontiers in endocrinology · 2026Pooled it
- Clinical and pathological profile with prognostic insights in 9504 thyroid cancer cases: a single-center study (2008-2023).Journal of the Endocrine Society · 2026Article
- A predictive nomogram for progression-free survival in radioiodine-refractory papillary thyroid carcinoma after reoperation: a longitudinal study in Vietnam.Endocrine journal · 2026Article
- Prognostic Factors and Recurrence in Papillary Thyroid Microcarcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Establishment of a nomogram model for predicting distant metastasis in oncocytic thyroid carcinoma: A retrospective cohort study.Medicine · 2026Article
- Investigating the effects of air pollution on papillary thyroid cancer based on network toxicology and molecular docking.Discover oncology · 2026Article
- A CRP-Albumin-Lymphocyte (CALLY) Index-Based Nomogram for Predicting Survival After Radical Surgery for Hypopharyngeal Squamous Cell Carcinoma.Journal of inflammation research · 2026Article
- Development and validation of a machine learning model for predicting high-risk distant metastatic recurrence in differentiated thyroid cancer.Frontiers in medicine · 2026Article
- The roles of both the endogenous synthesis and exogenous uptake of fatty acids in thyroid cancer cell proliferation.European journal of medical research · 2025Article
- Prognostic significance of GPR132 in papillary thyroid carcinoma: insights from integrated machine learning and its role in regulating TPC-1 cell growth.Discover oncology · 2025Article
- Article
- Safety and feasibility of robotic reoperation via a bilateral axillo-breast approach for patients with locally recurrent thyroid cancer: a single-center retrospective study.Gland surgery · 2025Article
- How Many Lymph Nodes are Enough in Thyroidectomy? A Cohort Study Based on Real-World Data.Annals of surgical oncology · 2025Article
- Narrative overview of possible preventive measures for differentiated thyroid carcinomas.Heliyon · 2025Review
- Article
- The Effect of Hemithyroidectomy in Papillary Thyroid Carcinoma with an Exclusive Involvement of the Recurrent Laryngeal Nerve: A Retrospective Study with a Propensity Score-Matched Analysis.Current oncology (Toronto, Ont.) · 2024Article
- F10 Gene Expression and Ethnic Disparities Present in Papillary Thyroid Carcinoma.Journal of personalized medicine · 2024Article
- Analysis of risk factors for papillary thyroid carcinoma and the association with thyroid function indicators.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The 2015 American Thyroid Association guidelines proposed recurrence risk stratification of differentiated thyroid carcinoma, including papillary thyroid carcinoma (PTC), but this stratification excluded non-initial treatment patients with worse outcomes. This study aimed to explore the potential risk factors for recurrence in PTC and develop a predictive model for both initial and non-initial treatment of patients with PTC. Methods: A total of 955 patients were included in this study. Differences between the recurrence (-) and recurrence (+) groups were compared. The 955 patients were randomized into two groups: the training group (671 cases) and the validation group (284 cases). All variables were selected using the LASSO regression analysis. A nomogram was developed based on the results of the univariate and multivariate logistic regression analyses. The nomogram performance was evaluated using discrimination and calibration. Results: Patients aged ≥55 years, extranodal extension (ENE), metastatic LN ratio (LNR) >0.5, and non-initial treatment were identified as potential risk factors for recurrence through LASSO regression and univariate and multivariate analyses. The receiver operating characteristic curve (ROC curve) showed high efficiency, with an area under the ROC curve (AUC) of 0.819 (95% confidence interval [CI], 0.729-0.909) and 0.818 (95% CI, 0.670-0.909) in the training and validation groups, respectively. The calibration curve indicated that the nomogram had a good consistency. Conclusion: In patients with PTC, age ≥55 years, ENE, LNR >0.5, and non-initial treatment are potential risk factors for recurrence. The predictive model of recurrence was confirmed to be a practical and convenient tool for clinicians to accurately predict PTC recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.